Paratek Closes $330M Optinose Purchase

Boston, MA, May 21, 2025 (Globe Newswire) -- Paratek Pharmaceuticals has acquired Optinose in a $330 million transaction, expanding its specialty therapeutics portfolio to include both NUZYRA® and XHANCE®. The deal is part of Paratek’s broader strategy to become a multi-product company addressing unmet medical needs. Shareholders of Optinose received $9 per share plus potential future payments tied to sales milestones of XHANCE.

Read full article here.